DanGer shock标准在Impella治疗急性心梗合并心源性休克中的适用性与结局:J-PVAD注册研究
本研究基于日本J-PVAD注册研究,纳入2020至2023年3975例接受Impella治疗的急性心肌梗死合并心源性休克(AMI-CS)患者,按DanGer shock标准分为五组。结果显示,符合DanGer shock标准的ST段抬高型心肌梗死相关心源性休克(STEMI-CS)患者占35.6%,30天死亡率为37.6%;不符合标准的STEMI-CS患者死亡率为27.6%,但随高龄、肾功能不全等因素显著升高。研究提示真实世界中Impella应用人群异质性强,需个体化风险评估。
要点
- 符合DanGer shock标准的STEMI-CS患者仅占Impella治疗AMI-CS人群的35.6%。
- 符合标准者30天死亡率为37.6%,不符合标准的STEMI-CS为27.6%。
- 非符合标准亚组结局异质,高龄、肾功能不全等与死亡率升高相关。
核心结论
- 在日本全国性注册研究中,约三分之一接受Impella治疗的AMI-CS患者符合DanGer shock标准。
- 不符合DanGer shock标准的亚组结局存在异质性,强调真实世界实践中需个体化风险评估以指导Impella使用。
研究设计与样本
- 基于J-PVAD注册研究的回顾性队列研究,纳入2020至2023年3975例接受Impella治疗的AMI-CS患者。
- 患者分为五组:符合标准的STEMI-CS、不符合标准的STEMI-CS、院外心脏骤停(OHCA)、机械并发症(MCs)和非ST段抬高型心肌梗死相关心源性休克(NSTEMI-CS)。
- 符合标准的STEMI-CS定义为满足全部以下条件:乳酸≥2.5 mmol/L、收缩压<100 mmHg或使用儿茶酚胺、左心室射血分数<45%、休克发作至首次Impella支持≤24小时。
主要发现
- 符合标准的STEMI-CS占所有AMI-CS病例的35.6%,30天死亡率为37.6%。
- 不符合标准的STEMI-CS患者30天死亡率为27.6%,但死亡率随高龄、肾功能不全、使用静脉-动脉体外膜氧合、室性心律失常或脓毒症而显著增加。
- OHCA组30天死亡率为51.3%(未恢复自主循环者63.4%),MCs组为39.8%,NSTEMI-CS组为33.3%。
关键数值与推荐
- 符合DanGer shock标准的STEMI-CS需同时满足:乳酸≥2.5 mmol/L、收缩压<100 mmHg或使用儿茶酚胺、左心室射血分数<45%、休克发作至首次Impella支持≤24小时。
临床怎么用
- 真实世界中Impella用于AMI-CS时,仅约三分之一患者符合DanGer shock标准,需注意不符合标准者的异质性结局。
- 对不符合DanGer shock标准的STEMI-CS患者,应结合高龄、肾功能不全、VA-ECMO使用、室性心律失常或脓毒症等因素进行个体化风险评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The DanGer shock trial showed a survival benefit of Impella in highly selected patients with ST-elevation myocardial infarction-related cardiogenic shock (STEMI-CS). In real-world settings, however, Impella is often used in broader populations not meeting trial criteria. This study aimed to assess the distribution and outcomes of DanGer shock-eligible and -ineligible acute myocardial infarction-related cardiogenic shock (AMI-CS) patients in a nationwide Japanese registry. METHODS: A total of 3975 AMI-CS patients treated with Impella between 2020 and 2023 were identified from the J-PVAD registry. Patients were stratified into five groups: eligible STEMI-CS, non-eligible STEMI-CS, out-of-hospital cardiac arrest (OHCA), mechanical complications (MCs), and non-STEMI-CS (NSTEMI-CS). Eligible STEMI-CS was defined as STEMI-CS fulfilling all of the following: lactate ≥ 2.5 mmol/L, systolic blood pressure <100 mmHg or catecholamine use, left ventricular ejection fraction <45%, and shock onset to first Impella support ≤24 h. Thirty-day mortality, associated risk factors, and complications were examined across the five groups. RESULTS: Eligible STEMI-CS accounted for 35.6% of all AMI-CS cases, with a 30-day mortality of 37.6%. Non-eligible STEMI-CS patients had lower mortality (27.6%), but it increased significantly with advanced age, renal dysfunction, veno-arterial extracorporeal membrane oxygenation use, ventricular arrhythmia, or sepsis. Thirty-day mortality was 51.3% in OHCA (63.4% without return of spontaneous circulation), 39.8% in MC, and 33.3% in NSTEMI-CS groups. CONCLUSIONS: In this nationwide registry, one-third of AMI-CS patients treated with Impella met DanGer shock criteria. Outcomes in non-eligible subgroups were heterogeneous, highlighting the importance of individualized risk assessment in guiding Impella use in real-world practice.
引用
- Arai, Kojima, Fukamachi, et al. DanGer shock criteria and outcomes in acute myocardial infarction-related cardiogenic shock treated with Impella: the J-PVAD registry. Eur Heart J. 2026. PMID: 41078250. doi:10.1093/eurheartj/ehaf787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。